Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Hope in Progress: American Parkinson Disease Association Supports Researchers With $1.975 Million in New Funding


News provided by

American Parkinson Disease Association (APDA)

Sep 07, 2023, 05:10 ET

Share this article

Share toX

Share this article

Share toX

APDA logo and tagline
APDA logo and tagline

From understanding levodopa induced dyskinesias to exploring environmental risk factors of PD, APDA-funded researchers pursue cutting-edge studies

NEW YORK, Sept. 7, 2023 /PRNewswire-PRWeb/ -- The American Parkinson Disease Association (APDA) has just awarded $1.975 million to support innovative Parkinson's disease (PD) research for the 2023-2024 funding year. The funded research projects will delve into key areas of PD biology including RNA regulation in levodopa-induced dyskinesia, cognitive impairment in PD, and physical activity among Latino/a PD patients, as well as the structure of mutant LRRK2, SARS-CoV-2 induced dopamine neuron damage, and so much more. APDA remains committed to funding promising projects to further our understanding of PD.

With someone diagnosed with PD every six minutes, this research is critical as we push for better treatments and ultimately, a cure. APDA is steadfast in its research focus – identifying and supporting researchers early in their careers to encourage them to either commence or continue dedicating themselves to PD research, as well as helping established investigators pursue new and novel ideas. Leslie A. Chambers, President & CEO of APDA comments, "Research support is a critical part of APDA's tagline 'Strength in optimism. Hope in progress'. We know that our funding allows researchers to jumpstart their ideas and obtain significant pilot data and initial proof of concept. In many instances, this then allows them to get further funding from National Institutes of Health and other funding institutions." Chambers continues, "We are very proud of our critical mission of providing seed funding for innovative projects that may never have gotten off the ground."

"Research support is a critical part of APDA's tagline 'Strength in optimism. Hope in progress'....We are very proud of our critical mission of providing seed funding for innovative projects that may never have gotten off the ground." -- Leslie A. Chambers, President & CEO, APDA

Post this

Grants for the year ahead have been awarded in the form of two Post-Doctoral Fellowships, seven Research Grants, two Diversity in Parkinson's Disease Research grants, eight APDA Centers for Advanced Research, and one George C. Cotzias Memorial Fellowship, APDA's most prestigious award.

For the fourth year in a row, APDA is awarding a specialized grant to two researchers focused on diverse and under-represented communities. APDA created the first-of-its-kind Diversity in Parkinson's Disease Research Grant in 2019 to encourage and support researchers who are committed to diversity-focused research so we can learn more about how the disease affects different populations and ultimately better serve people with PD from all communities.

All APDA grants are awarded through a competitive application process and reviewed by APDA's Scientific Advisory Board (SAB) which is comprised of scientists with a wide array of backgrounds and expertise in all areas relevant to PD research. The SAB meets annually to review all grant proposals and set the scientific direction of APDA's annual research investment. "Once again our Scientific Advisory Board reviewed many excellent applications and had to make difficult decisions about whom to fund" states Rebecca Gilbert, MD, PhD, and Chief Scientific Officer, APDA. "I am very proud of the many promising projects that we are funding this year."

The 2023-2024 APDA Research Grants

The George C. Cotzias Fellowship is APDA's most prestigious grant and is awarded to a young physician-scientist with exceptional promise who is establishing a career in research, teaching, and clinical services relevant to Parkinson's. The award spans three years and is designed to fund a long-range project focused on PD. This year's awardee is:

  •     Krithi Irmady, MD, PhD -- The Rockefeller University, New York, NY

RNA regulation in Parkinson's disease and levodopa-induced dyskinesia

APDA Diversity in Parkinson's Disease Research Grants are one-year grants to study the health inequities and/or differences among under-studied PD communities, across the spectrum of ethnicity, ancestry, geography, socioeconomic conditions, and gender. This year's awardees are:

  •     Karen Hegland, PhD -- University of Florida, Gainesville, FL

Low utilization of deep brain stimulation (DBS) therapy among minoritized individuals with Parkinson's disease

  •     Laura Andrea Prieto, PhD-- University of Wisconsin-Madison, Madison, WI

Physical activity among Latino/a people with Parkinson's disease and their care partners

Post-Doctoral Fellowships are awarded to support post-doctoral scientists who recently completed their PhD work and whose research holds promise to provide new insights into the pathophysiology, etiology, and treatment of PD. This year's awardees are:

  •     Abdulmunaim Eid, MD -- Washington University in St. Louis, St. Louis, MO

The neurobiological basis of Parkinson's disease clinical subtypes

  •     Naemeh Pourshafie, PhD -- The Trustees of the University of Pennsylvania, Philadelphia, PA

Enhancing neuronal resilience to neurodegeneration via the epigenetic-metabolic axis

Research Grants are awarded to investigators performing innovative PD research at major academic institutions across the United States. This year's awardees are:

  •     Andrew Arrant, PhD -- University of Alabama at Birmingham, Birmingham, AL

Investigating the role of progranulin in synucleinopathy

  •     Briana De Miranda, PhD -- University of Alabama at Birmingham, Birmingham, AL

Cdk5 inhibition as a protective mechanism against environmental toxicant induced Parkinson's disease

  •     Jeffrey Eells, PhD -- East Carolina University, Greenville, NC

Mechanisms of SARS-CoV-2 infection induced dopamine neuron damage

  •     Enrico Opri, PhD -- The Regents of the University of Michigan, Ann Arbor, MI

Stimulation induced evoked potentials for guided intra and post-operative functional mapping

  •     Nikhil Panicker, PhD -- Cleveland Clinic Foundation, Cleveland, OH

Using IPSC models to interrogate Inflammasome-mediated pathogenesis in Parkinson's Disease

  •     Satya Surabhi, PhD -- Albert Einstein College of Medicine, Bronx, NY

The role of Lamp1 in age-related neurodegenerative diseases

  •     William Zeiger, MD, PhD -- University of California – Los Angeles, Los Angeles, CA

Mechanisms of posterior cortical circuit dysfunction and cognitive impairment in a mouse model of PD

In addition, continued funding was granted for eight APDA Centers for Advanced Research to support various programs including research trainees, clinical fellowship programs, early-stage discovery programs and later-stage clinical translation. These Centers facilitate research that is at the forefront of investigation into the causes, treatments and ultimately the cure for PD. The current APDA Centers for Advanced Research are:

  •     Boston University School of Medicine, Boston, MA
  •     Emory University School of Medicine, Atlanta, GA
  •     Mayo Clinic, Jacksonville, FL
  •     Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
  •     The Brigham and Women's Hospital, Boston, MA
  •     University of Alabama at Birmingham School of Medicine, Birmingham, AL
  •     University of Pittsburgh Medical Center, Pittsburgh, PA
  •     Washington University School of Medicine, St. Louis, MO

"We are confident that the projects that we are currently funding will have a high impact on further understanding Parkinson's disease," states Chambers. "This work is only possible because of the support of our generous APDA donors."

Learn more about these grantees and the exciting work they are doing and browse all APDA-funded research by visiting http://www.apdaparkinson.org/research/what-we-fund/.

Researchers and physicians who are interested in applying for APDA funding can visit http://www.apdaparkinson.org/research for details on the 2024-2025 funding opportunities. Letters of Intent for the 2024-2025 grant cycle can be submitted starting September 28, 2023, with a deadline of December 2, 2023.

Those who want to support APDA's critical research with a donation can do so by visiting http://www.apdaparkinson.org/donate or mailing a check payable to APDA to: APDA, PO Box 61420, Staten Island, NY 10306.

The American Parkinson Disease Association (APDA) is a nationwide grassroots network dedicated to fighting Parkinson's disease (PD) and works tirelessly to help the approximately one million people in the United States with PD live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $252 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. To join us in the fight against Parkinson's disease and to learn more about the support APDA provides nationally through our network of Chapters and Information & Referral (I&R) Centers, as well as their national Research Program and Centers for Advanced Research, please visit http://www.apdaparkinson.org.

Media Contact
Eloise Caggiano, American Parkinson Disease Association (APDA), 718.737.8151, [email protected], www.apdaparkinson.org

SOURCE American Parkinson Disease Association (APDA)

Modal title

APDA press release announcing $1.975 million in Parkinson's disease research grants
View PDF
APDA press release announcing $1.975 million in Parkinson's disease research grants
APDA press release announcing $1.975 million in Parkinson's disease research grants

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.